CATALOGO DEI PRODOTTI DELLA RICERCA

CAMINATI, Marco
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 7.651
EU - Europa 6.538
AS - Asia 5.987
SA - Sud America 877
Continente sconosciuto - Info sul continente non disponibili 294
AF - Africa 223
OC - Oceania 8
Totale 21.578
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 7.437
RU - Federazione Russa 3.311
SG - Singapore 2.614
CN - Cina 1.321
IT - Italia 1.110
BR - Brasile 667
VN - Vietnam 607
HK - Hong Kong 566
GB - Regno Unito 449
FR - Francia 348
DE - Germania 332
IE - Irlanda 295
SE - Svezia 261
BD - Bangladesh 228
KR - Corea 177
FI - Finlandia 122
IN - India 112
CA - Canada 107
JP - Giappone 77
AR - Argentina 72
MX - Messico 66
NL - Olanda 58
ES - Italia 54
ID - Indonesia 51
PL - Polonia 47
ZA - Sudafrica 46
NG - Nigeria 41
TR - Turchia 40
BJ - Benin 37
IQ - Iraq 37
TG - Togo 37
CO - Colombia 32
UA - Ucraina 31
VE - Venezuela 30
AT - Austria 28
EC - Ecuador 25
SA - Arabia Saudita 22
BE - Belgio 19
CL - Cile 18
PK - Pakistan 18
MA - Marocco 14
UZ - Uzbekistan 14
PY - Paraguay 13
LT - Lituania 12
PH - Filippine 12
CR - Costa Rica 11
JO - Giordania 11
AZ - Azerbaigian 10
KE - Kenya 9
MY - Malesia 8
NO - Norvegia 8
NP - Nepal 8
PE - Perù 8
AE - Emirati Arabi Uniti 7
CH - Svizzera 7
LB - Libano 7
UY - Uruguay 7
AU - Australia 6
BG - Bulgaria 6
EG - Egitto 6
JM - Giamaica 6
SC - Seychelles 6
AL - Albania 5
CZ - Repubblica Ceca 5
IL - Israele 5
DO - Repubblica Dominicana 4
DZ - Algeria 4
KZ - Kazakistan 4
LV - Lettonia 4
OM - Oman 4
RS - Serbia 4
SN - Senegal 4
TT - Trinidad e Tobago 4
BH - Bahrain 3
BO - Bolivia 3
BY - Bielorussia 3
ET - Etiopia 3
GH - Ghana 3
HN - Honduras 3
HU - Ungheria 3
RO - Romania 3
TH - Thailandia 3
XK - ???statistics.table.value.countryCode.XK??? 3
BB - Barbados 2
CI - Costa d'Avorio 2
DM - Dominica 2
EU - Europa 2
GP - Guadalupe 2
HR - Croazia 2
KG - Kirghizistan 2
LK - Sri Lanka 2
LY - Libia 2
MD - Moldavia 2
MG - Madagascar 2
NI - Nicaragua 2
PT - Portogallo 2
QA - Qatar 2
SK - Slovacchia (Repubblica Slovacca) 2
SR - Suriname 2
SY - Repubblica araba siriana 2
Totale 21.257
Salva come PNG Salva come JPEG
Città #
Singapore 1.346
Ashburn 1.101
Moscow 1.100
San Jose 944
Dallas 773
Chandler 604
Hong Kong 555
Council Bluffs 485
New York 364
Verona 360
Beijing 310
The Dalles 308
Dublin 290
Southend 245
Ho Chi Minh City 185
Los Angeles 160
Hanoi 132
Lawrence 120
Princeton 120
Sindelfingen 102
Wilmington 97
Buffalo 93
Milan 86
Jacksonville 83
Munich 79
Redondo Beach 71
Santa Clara 68
London 67
Tokyo 67
São Paulo 66
Columbus 64
Jinan 64
Helsinki 59
Ann Arbor 56
Rome 54
Nanjing 49
Hebei 46
Woodbridge 46
Shenyang 44
Guangzhou 43
Warsaw 42
Redwood City 41
Boardman 40
Redmond 40
Turku 40
Abuja 38
Cotonou 37
Orem 37
Amsterdam 36
Lomé 36
Denver 35
Brooklyn 34
Chennai 34
Zhengzhou 32
Bologna 31
Johannesburg 31
Seattle 31
Montreal 30
Dong Ket 29
Da Nang 28
Houston 28
Phoenix 28
Haikou 27
Haiphong 27
Nuremberg 27
Jakarta 26
Ningbo 26
Toronto 26
Poplar 25
San Francisco 24
Tianjin 24
Boston 23
Frankfurt am Main 23
Changsha 22
Atlanta 21
Mexico City 21
Norwalk 21
Stockholm 21
Kent 20
Mumbai 20
Naples 20
Chicago 19
Rio de Janeiro 19
Taiyuan 18
Brussels 16
Taizhou 16
Falkenstein 15
Hangzhou 15
Turin 15
Shanghai 14
Tashkent 14
Bari 13
Curitiba 13
Lappeenranta 13
Manchester 13
Nanchang 13
Querétaro 13
Vienna 13
Ankara 12
Baghdad 12
Totale 12.384
Salva come PNG Salva come JPEG
Nome #
Dupilumab-induced hypereosinophilia: review of the literature and algorithm proposal for clinical management 461
Fatal asthma; is it still an epidemic? 210
Safety of Biologic Therapies for Severe Asthma: An Analysis of Adverse Reactions Reported in the WHO Pharmacovigilance Database 199
Allergic rhinitis: pharmacotherapy in pregnancy and old age 187
Allergen specific sublingual immunotherapy in children with asthma and allergic rhinitis 185
Asthmatic patients in COVID-19 outbreak: Few cases despite many cases 183
COVID-19 Vaccination in Patients with Severe Asthma on Biologic Treatment: Safety, Tolerability, and Impact on Disease Control 182
Asthma in a large COVID-19 cohort: Prevalence, features, and determinants of COVID-19 disease severity 181
Asthma control in primary care: the results of an observational cross-sectional study in Italy and Spain 179
Drop-out rate among patients treated with omalizumab for severe asthma: Literature review and real-life experience 173
Adverse reaction to local anaesthetics: Is it always allergy? 173
Allergic sensitization to common pets (cats/dogs) according to different possible modalities of exposure: an Italian Multicenter Study 171
A hierarchical cluster analysis of the psycological impact of the COVID-19 pandemic on Italian severe asthma patients 167
Asthma and anaphylaxis 167
Clinical response to biologicals for severe asthma: any relevance for sex in different age ranges? 161
Onset of eosinophilic granulomatosis with polyangiitis in a patient treated with an IL-5 pathway inhibitor for severe asthma 161
Biologics for Eosinophilic Granulomatosis with Polyangiitis: one size does not fit all 160
Allergen Immunotherapy Adherence in the Real World: How Bad Is It and How Can It Be Improved? 159
Evaluation of asthma control in the pharmacy: an Italian cross-sectional study 157
Asthma under/misdiagnosis in primary care setting: an observational community-based study in Italy 157
Importance of Cardiopulmonary Exercise Testing amongst Subjects Recovering from COVID-19 157
Successful switching from mepolizumab to dupilumab in a patient with EGPA in remission phase and persistent nasal polyposis 157
Allergy and Sexual Behaviours: an Update 154
Periostin: The bone and beyond 154
Allergen-specific immunotherapy and COVID-19: What happened? 153
Thunderstorm Asthma: A Critical Appraisal Based on Clinical Practice 152
COVID-19 in severe asthmatic patients during ongoing treatment with biologicals targeting type 2 inflammation: Results from a multicenter Italian survey 152
Low‑dose anti‑IL 5 treatment in idiopathic hypereosinophilic syndrome: towards a precision medicine approach for remission maintenance 150
Biologics and global burden of asthma: A worldwide portrait and a call for action 149
Asthma control in severe asthmatics under treatment with omalizumab: A cross-sectional observational study in Italy 148
Anaphylaxis and intimate behaviour 147
Anti-IL-5 and IL-5Ra: Efficacy and Safety of New Therapeutic Strategies in Severe Uncontrolled Asthma 147
Profiling blood hypereosinophilia in patients on dupilumab treatment for respiratory conditions: a real-life snapshot 146
Anxiety and Depression Effects During Drug Provocation Test 146
New horizons for the treatment of severe, eosinophilic asthma: benralizumab, a novel precision biologic 145
ALLERGY AND CORONAVIRUS DISEASE (COVID-19) INTERNATIONAL SURVEY: REAL-LIFE DATA FROM THE ALLERGY COMMUNITY DURING THE PANDEMIC 144
Idiopathic hypereosinophilic syndromes and rare dysimmune conditions associated with hyper-eosinophilia in practice: An innovative multidisciplinary approach 142
[Fractional exhaled nitric oxide measurement during specific inhalation challenge tests] 141
Mepolizumab for severe eosinophilic asthma: a real-world snapshot on clinical markers and timing of response 140
Mepolizumab 100 mg in severe asthmatic patients with EGPA in remission phase 140
Benralizumab Efficacy in Late Non-Responders to Mepolizumab and Variables Associated with Occurrence of Switching: A Real-Word Perspective 139
Anaphylaxis and Coronavirus Disease 2019 vaccine: a danger relationship? 139
Timing of response and long term efficacy of Omalizumab in non-clonal Mast Cell Activation Syndrome: A case series 139
Biologics for the Treatment of Allergic Conditions: Eosinophil Disorders 139
The potential role of local pharmacies to assess asthma control: an Italian cross-sectional study 139
Hidden Comorbidities in Asthma: A Perspective for a Personalized Approach 138
Incidence and risk factors for subcutaneous immunotherapy anaphylaxis: the optimization of safety 138
COPD prevalence in a north-eastern Italian general population 137
Relationship between hair shedding and systemic inflammation in COVID-19 pneumonia 136
Balancing efficacy against safety in sublingual immunotherapy with inhalant allergens: what is the best approach? 131
Adherence to Intranasal Steroids in Chronic Rhinosinusitis with Nasal Polyposis Prior to and during Biologic Therapy: A Neglected Matter 126
What lies beyond Asthma Control Test: Suggestions for clinical practice 126
Eosinophilic Granulomatosis With Polyangiitis and Cardiac Involvement: A Case Report 126
Relevance of TH2 markers in the assessment and therapeutic management of severe allergic asthma: A real-life perspective 124
Uncontrolled Asthma: Unmet Needs in the Management of Patients 124
Omalizumab management beyond clinical trials: the added value of a network model 123
Effects of specific allergen immunotherapy on biological markers and clinical parameters in asthmatic children: a controlled-real life study 123
Trends and determinants of Emergency Room admissions for asthma: A retrospective evaluation in Northeast Italy 122
Different aspects of severe asthma in real life: Role of Staphylococcus aureus enterotoxins and correlation to comorbidities and disease severity 122
Benralizumab for eosinophilic granulomatosis with polyangiitis: a retrospective, multicentre, cohort study 120
Safety of uSCIT-MPL-4: prevalence and risk factors of systemic reactions in real life 120
Diagnosis, management and therapeutic options for eosinophilic esophagitis 118
Safety of Biological Therapies for Severe Asthma: An Analysis of Suspected Adverse Reactions Reported in the WHO Pharmacovigilance Database 118
Choosing wisely: practical considerations on treatment efficacy and safety of asthma in the elderly 118
Comment on: Onset of eosinophilic granulomatosis with polyangiitis in a patient treated with an IL-5 pathway inhibitor for severe asthma: reply 118
SANI-Severe Asthma Network in Italy: a way forward to monitor severe asthma 117
Asthma management among different specialists: results from a national Italian survey 117
Premature aging of the immune system affects the response to SARS-CoV-2 mRNA vaccine in β-Thalassemia: additional dose role 116
Relevance of Smoking Habit in Severe Asthma Patients: Evidence from the Severe Asthma Network in Italy (SANI) Registry 116
Unlocking the Long-Term Effectiveness of Benralizumab in Severe Eosinophilic Asthma: A Three-Year Real-Life Study 116
Profiling severe asthma: Any relevance for age? An analysis from Severe Asthma Network Italy (SANI) cohort 116
Epidemiology of the relationship between allergic bronchopulmonary aspergillosis and asthma 115
Efficacy of Benralizumab in severe asthma in real life and focus on nasal polyposis 114
Oral CorticoSteroid sparing with biologics in severe asthma: A remark of the Severe Asthma Network in Italy (SANI) 114
The pathogenesis, epidemiology and biomarkers of susceptibility of pulmonary fibrosis in COVID-19 survivors 113
Targeting eosinophils: severe asthma and beyond 113
Low adherence to inhaled corticosteroids/long-acting β2-agonists and biologic treatment in severe asthmatics 113
Remission in Type 2 Inflammatory Diseases: Current Evidence, Unmet Needs, and Suggestions for Defining Remission in Chronic Rhinosinusitis with Nasal Polyps 113
Severe refractory asthma: current treatment options and ongoing research 112
Towards precision medicine: The application of omics technologies in asthma management 112
Diagnosis and Management of Allergic Rhinitis in Asthmatic Children 112
Extracellular Vesicles in Asthma: Intercellular Cross-Talk in TH2 Inflammation 111
One year of mepolizumab. Efficacy and safety in real-life in Italy 111
Sex in Respiratory and Skin Allergies 111
How far from correct is the use of adrenaline auto-injectors? A survey in Italian patients 111
Asthma severity: the patient’s point of view 110
Aspergillus fumigatus and personalized medicine: Toward a clinically reliable algorithm 110
Omalizumab for severe allergic asthma in clinical trials and real-life studies: what we know and what we should address 109
Sex Differences in Severe Asthma: Results From Severe Asthma Network in Italy-SANI 109
Component resolved diagnosis (CRD): how much is it presently used by Italian allergists? 107
Higher blood eosinophil levels after omalizumab treatment may be associated with poorer asthma outcomes 107
Inflammatory and senescence-associated mediators affect the persistence of humoral response to COVID-19 mRNA vaccination in transfusion-dependent beta-thalassemic patients 106
Biologic Therapy in a Patient with Asthma and Nasal Polyps 106
Dupilumab Efficacy on Asthma Functional, Inflammatory, and Patient-Reported Outcomes across Different Disease Phenotypes and Severity: A Real-Life Perspective 105
Severe Asthma Network Italy Definition of Clinical Remission in Severe Asthma: A Delphi Consensus 105
Serum biomarkers of remodeling in severe asthma with fixed airway obstruction and the potential role of KL-6 104
Oral health in asthmatic patients: a review: Asthma and its therapy may impact on oral health 104
Safety of dupilumab in T2 airways conditions: focus on eosinophilia across trials and real-life evidence 103
Serum periostin during omalizumab therapy in asthma: A tool for patient selection and treatment evaluation 102
Italian study on buckwheat allergy: prevalence and clinical features of buckwheat-sensitized patients in Italy 102
Totale 13.802
Salva come PNG Salva come JPEG
Categoria #
all - tutte 86.033
article - articoli 85.736
book - libri 0
conference - conferenze 297
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 172.066
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022620 0 176 15 43 15 14 7 50 50 12 58 180
2022/20231.926 145 138 223 221 217 452 43 106 240 12 80 49
2023/20241.487 57 102 124 196 117 345 110 61 19 62 194 100
2024/20253.674 177 215 155 507 136 92 115 346 581 266 303 781
2025/202611.855 813 706 774 1.892 2.995 758 1.066 693 873 551 287 447
2026/2027578 178 400 0 0 0 0 0 0 0 0 0 0
Totale 21.578